Noopur S. Raje, MD, a medical oncologist at Massachusetts General Hospital, discusses chimeric antigen receptor T-cell therapy in patients with multiple myeloma. This therapy has been an exciting advancement in both hematology as well as solid tumors, she notes.
Noopur S. Raje, MD, a medical oncologist at Massachusetts General Hospital, discusses chimeric antigen receptor (CAR) T-cell therapy in patients with multiple myeloma. This therapy has been an exciting advancement in both hematology as well as solid tumors, she notes.
Research has been investigating the use of CAR T cells in combination with bb2121 and a lentiviral vector. This recognizes humanized BCMA, Raje explains. The addition of 4-1BB to this also helps with a slow and consistent expansion of the T cells, which also has less toxicity.
Brain Cancer Awareness Month: Challenges and Innovations in Treatment
May 13th 2024In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.
Read More
How BCMA CAR T-Cell Therapy Provides Later-Line Options in R/R Multiple Myeloma
May 10th 2024During a Case-Based Roundtable® event, Abdullah Khan, MBBS, discussed the different outcomes with idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma in both the clinic and real-world settings in the second article of a 2-part series.
Read More